Table 5 Demographic characteristics of subjects with and without change in MSSA colonization, number (%) of subjects (N = 58) c
From: Antimicrobial resistance acquisition after international travel in U.S. travelers
|  | No change in MSSA (n = 49) | Change in MSSA (n = 9) |
|---|---|---|
Male gender | 18 (37) | 6 (67) |
Age, median (minimum-maximum) | 64 (15–82) | 55 (18–81) |
Regiona | ||
 Mexico, Caribbean, & Central America | 16 (33) | 2 (22) |
 Asia | 14 (29) | 3 (33) |
 Africa | 14 (29) | 2 (22) |
 Europe | 4 (8) | 1 (11) |
 South America | 1 (2) | 1 (11) |
 North America | 2 (4) | 0 |
Purpose of travela | ||
 Vacation | 37 (76) | 6 (67) |
 Visiting friends and relatives | 7 (14) | 3 (33) |
 Other (missionary/volunteer) | 5 (10) | 0 |
 Deployment and military duty | 3 (6) | 1 (11) |
 School | 1 (2) | 0 |
Duration of travel, median (minimum-maximum) | 12 (6–105) | 12 (8–42) |
Living conditionsa | ||
 Hotel | 31 (63) | 5 (56) |
 Friends and relatives | 10 (20) | 3 (33) |
 Group livingb | 10 (20) | 0 |
 Boat/cruise | 6 (12) | 1 (11) |
Local water ingestion during travel | 24 (49) | 3 (33) |
Water exposures during travel | 18 (37) | 2 (22) |
Antibiotic exposure since enrollment | 18 (37) | 5 (56) |
 Malaria chemoprophylaxis | 17 (35) | 5 (56) |
  Atovaquone/Proguanil | 15 (31) | 2 (22) |
  Doxycycline | 1 (2) | 2 (22) |
  Chloroquine | 1 (2) | 1 (11) |
 Antibiotics for traveler’s diarrhea since enrollment | 3 (6) | 0 |
  Ciprofloxacin | 2 (4) | 0 |
  Erythromycin | 1 (2) | 0 |
 Systemic antibiotics for other indications since enrollment | 3 (6) | 0 |
  Azithromycin | 1 (2) | 0 |
  Cephalexin | 1 (2) | 0 |
  Unknown antibiotic | 1 (2) | 0 |
Illness since enrollment | 13 (27) | 0 |
Duration of illness, median (minimum-maximum) | 4 (1–27) | n/a |